Controlled-Release Low Density Effervescent Floating Matrix Tablets of Risperidone: Development, Optimization, in vitro-in vivo Evaluation in Healthy Human Volunteers and Determination of Dissolution Equivalency Formulation and evaluation of floating matrix tablet of Risperidone in human volunteer
Iranian Journal of Pharmaceutical Sciences,
Vol. 9 No. 2 (2013),
1 April 2013
,
Page 31-48
https://doi.org/10.22037/ijps.v9.40899
Abstract
The main objective of the present study was to formulate gastroretentive effervescent sustained release drug delivery systems of risperidone floating tablets with the help of Methocel® K15, Ethocel® standard 7FP premium, Eudragit ® RS100 sustained release polymers to improve its safety profile, bioavailability and patient compliance. Risperidone floating tablets were formulated by wet granulation technique by using citric acid and sodium bicarbonate as a gas generating agent. Methocel® K15, Ethocel® standard 7FP premium, Eudragit® RS 100 were used to formulate floating effervescent sustained release tablets. Preliminary trials were done to investigate matrix integrity and floating behavior. On the basis of preliminary trials, various formulations were designed to optimize the best formulation. The FDA recommended statistical approach was used to test dissolution equivalency. Preliminary studies showed better floating behavior, but poor matrix integrity with Methocel®K15 containing formulations. Moreover, Ethocel® standard 7FP premium and Eudragit® RS 100 containing formulations showed better matrix integrity but poor floating behavior. Formulations RSFTIII, RSFTVI, RSFTIX were optimized and showed the drug release for 10 hours. Dissolution equivalency was tested for optimized formulation and found equivalent. In vivo-study also showed gastric retention time more than 4 hours.
- Antipsychotic drug
- Dissolutionequivalency
- Eudragit RS 100
- Ethylcellulose
- Floating drug delivery system
- Gastroretentive drug delivery system
- Hydrodynamically balanced system
- Risperidone.
How to Cite
References
[2] Shah SH, Patel JK, Patel NV.Stomach specific floating drug delivery system: a review. IJPTR. (2009)1(3):623-633.
[3] NayakAK, Maji R, DasB. Gastroretentive drug delivery systems: a review. AJPCR (2010) 3 (1): 1-10.
[4] Mayavanshi AV, Gajjar SS. Floating drug delivery systems to increase gastric retention of drugs: a review. RJPT(2008) 1 (4): 345-348.
[5] BhiseSB,Aloorkar NH. Formulation and in vitro evaluation of floating capsules of theophylline.IJPS(2008)70 (2): 224-227.
[6] Savable M, Vani T, PhaneendarR, VashdevaiahA. Formulation and evaluation of gastroretentiveglipizide floating tablets.IJCP(2011) 2 (1): 1-4.
[7] PonchelG,IracheJM.Specific and nonspecific bioadhesive particulate system for oral delivery to the gastrointestinal tract. JADDR(1998) 34:191-219.
[8] Uzdemir N, OrduS,Ozkan, Y. Studies of floating dosage forms of furosemide: in vitroandinvivoevaluation of bilayer tablet formulations. DDIP(2000)26:857–866.
[9] Klausner EA, Lavy E, Friedman M, Hoffman A. Expandable gasteroretentive dosage form.JCR (2003)90 (2): 143-162.
[10] Singh BN, Kim HK. Floating drug delivery systems: an approach to oral controlled drug delivery via gastric retention. JCR (2000) 63:235-59.
[11] Hendset M, Haslemo T, Rudberg, I, RefsumH,Molden E. The complexity of active metabolites in therapeutic drug monitoring of psychotropic drugs.JP (2006) 39 (4): 121–7.
[12] Leon J, Susce M, Pan R, Wedlund P, OrregoM, Diaz F. A study of genetic (CYP2D6 and ABCB1) and environmental (drug inhibitors and inducers) variables that may influence plasma risperidone levels.JP(2007) 40 (3): 93–102.
[13] Titusville NJ. In: Physician’s desk reference Risperdal® Tablets, JPI(2005) 59:662-667.
[14] Williams R.Optimal dosing with risperidone: updated recommendations. JCP(2001) 62:282–289.
[15] Ascher SH, Faries D, Zhu B, Ernst F, Swartz M ,Swanson. Medication adherence and long-term functional outcomes in the treatment of schizophrenia in usual care.JCP (2006) 67 (3): 453.
[16] Ray W, Chung C, Murray K, Hal, K , Stein .Atypical antipsychotic drugs and the risk of sudden cardiac death. TNEJM (2009) 360 (3): 225.
[17] Badshah A, Subhan F, Raufk, BukhariNI,Shah K. Development of controlled-release matrix Tablet of risperidone: Influence of Methocel®- and Ethocel®-based novel polymeric blend on in vitro drug release and bioavailability.IJAAPS(2011) 12 (2): 525–533.
[18] Sanjay SP, RayS, Thakur RS.Formualtion and evaluation of floating drug delivery system containing clarithromycin for Helicobacter Pylori.JAPDR(2006) 63 (1): 53-61.
[19] Tabandeh H, Mortazavi SA, GuilaniTB. Preparation of sustained release matrix tablets of Aspirin with Ethylcellulose, Eudragit RS100 and Eudragit S100 and studying the release profiles and their sensitivity to tablet hardness. IJPR (2003): 201-206.
[20] Rosa, Jimenez-Castellanos M, Zia H, RhodesCT. Dosing and testing in vitro of abioadhesive and a floating drug deliverysystem for oral application. IJP (1994)105 (1): 65-70.
[21] Sriamornsak P, Thirawong N ,Korkard K. Swelling, erosion and release behavior of alginate-based matrix tablets. EJPB (2007) 66:435–50.
[22] Rahman Z, AliM,Khar RK. Design and evaluation of bilayer floating tablets of captopril.AP (2006) 56: 49-57.
[23] Bhowmik D, ChiranjiB,Chandira M. Floating drug delivery system: a review.DPL(2009)1 (2): 199-218.
[24] Huang YB, Tsai YH, Yang WC, Wu PC and Chang JS. Optimization of sustained release propranolol dosage form using factorial design and response surface methodology. BPB(2004) 27 (10): 1626–9.
[25] NajibN, Suleiman M. The kinetics of drug release from Ethylcellulose solid dispersions.DDIP(1985)11:2169-2189.
[26] Desai SJ, Singh P, SimonelliAP, Higuchi WI. Investigation of factors influencing release of solid drug dispersed in wax matrices III. Quantitative studies involving polyethylene plastic matrix. JPS(1966) 55:1230-1234.
[27] Higuchi. Mechanism of sustained action medication. Theoretical analysis of rate of release of solid drugs dispersed in sold matrices. JPS(1963) 50:1145-1149.
[28] Hixson AW, Crowell JH. Dependence of reaction velocity upon surface and agitation.IEC(1931) 23:923-931.
[29] Li S, Shen Y, Li W, Hao X. A common profile for polymer-based controlled release and its logical interpretation to general release process.JPPS (2006) 9 (2): 238-244.
[30]Shah VP, Tsong, Y, SatheP, Liu JP.In vitro dissolution profile comparison-statistics and analysis of the similarity factor, f2. JPR(1998)15 (6): 889–896.
[31] FassahiR, Pillay V. Evaluation and comparison of dissolution data derived from different modified release dosage forms: an alternative method. JCR (1998) 55 (1): 45-55.
[32] Rockville MD, US FDA. Guidance for industry. Dissolution testing of immediate release solid oral dosage forms. US FDA CDER(1997).
[33] GohelMC,Panchal M. Refinement of lower acceptance value of the similarity factor f2in comparison of dissolution profile. DT (2002) 9:18-22.
[34] Singhvi G, Singh R.In vitro drug release characterization models.IJPSR(2011)II (I): 3-10.
[35] Deshpande AA, Shah NH, Rhodes CT, Malick W. Development of a novel controlled-release system for gastric retention. JPR(1997)149 (6): 815-819.
- Abstract Viewed: 336 times
- IJPS_Volume 9_Issue 2_Pages 31-48 Downloaded: 209 times